Albumin‐bilirubin score is superior to platelet‐albumin‐bilirubin score and model for end‐state liver disease sodium for predicting posthepatectomy liver failure

Abstract

Background Risk stratification for patients undergoing hepatectomy can be attempted using established models. This study compares the platelet‐albumin‐bilirubin (PALBI) score with albumin‐bilirubin (ALBI) and model for end‐stage liver disease sodium (MELD‐Na) for predicting posthepatectomy liver failure (PHLF) and 30‐day mortality. Methods The 2014–2018 NSQIP database was queried for patients who underwent elective hepatectomy. Multivariable logistic regressions assessed associations of posthepatectomy outcomes with patient and clinical characteristics. Predictive accuracy of the grading systems was evaluated using receiver operator characteristic (ROC) curves and calculating area under the curve (AUC). Results Severe PHLF (Grade B/C) and mortality were present in 2.58% (N = 369) and 1.2% (N = 171) of patients who underwent hepatectomy (N = 13 925), respectively. ALBI Grade 2/3 had a stronger association with severe PHLF (odds ratio [OR] = 1.62, p < 0.01) and mortality (OR = 2.06, p < 0.005) than PALBI Grade 2/3 (OR = 1.14, p = 0.43 for PHLF and OR = 2.01, p < 0.005 for mortality) or MELD‐Na ≥10 (OR = 1.29, p = 0.25 for PHLF and OR = 1.84, p < 0.03). ALBI had a higher AUC (0.671) than PALBI (0.625) and MELD‐Na (0.627) for predicting severe PHLF. ALBI had a higher AUC (0.695) than PALBI (0.642) for predicting 30‐day mortality. Conclusions ALBI was a more accurate predictor of severe PHLF and 30‐day mortality than MELD‐Na and PALBI for patients who underwent hepatectomy.